Phase II Study of Calcitonin for Tumoral Calcinosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004358|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis.
II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.
IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
|Condition or disease||Intervention/treatment||Phase|
|Calcinosis||Drug: calcitonin||Phase 2|
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin every 3 weeks. Ondansetron premedication and intravenous hydration are also administered.
Patients are followed for disease progression and tumor recurrence.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||9 participants|
|Study Start Date :||November 1992|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004358
|United States, Illinois|
|Children's Memorial Hospital, Chicago|
|Chicago, Illinois, United States, 60614|
|Study Chair:||Craig B. Langman||Ann & Robert H Lurie Children's Hospital of Chicago|